https://doi.org/10.4081/mm.2013.3265

New marker for follow up of anti-HBV - retrospective study

Vol. 28 No. 3 (2013)
Submitted: 18 March 2014
Accepted: 18 March 2014
Published: 18 March 2014
Chronic hepatitis B, Quantitative HbsAg, Sustained Immunological Control (SIC)
Abstract Views: 734
PDF: 1135
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Francesca Camilli
checcamilli@libero.it
Marianna Saracino
Hepatitis related to HBV manifests itself in many forms and can be treated with excellent results in the acute phase whereas, in the chronic phase, only a sustained immunological control (SIC) in time can be achieved. The current gold standard test for therapy is the quantitative HBV DNA which, by itself, does not allow an assessment of the SIC. For the reason we did a retrospective study of 13 patients over a 19 month period during which we simultaneously evaluated both HBV DNA and the new marker: quantitative HbsAg; this test was carried out in house. The relationship that exists between the markers and which could provide the clinician with more information was evaluated in three types: High similarity, Low similarity, No similarity between the performance curves of the two markers probably connected by many types of therapeutic answers: sustained immunological control, low immunological control and no immunological control.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Camilli, F., & Saracino, M. (2014). New marker for follow up of anti-HBV - retrospective study. Microbiologia Medica, 28(3). https://doi.org/10.4081/mm.2013.3265

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.